Novo Pharma released full results Monday from a late-stage trial showing Wegovy reduced body mass index by 19.7 percentage points on average compared with placebo in children ages 6 to under 12 after 68 weeks, with BMI falling 17.4% among drug recipients and rising 2.2% among those on placebo.
When including all 167 children in the study regardless of treatment discontinuation, Wegovy lowered BMI by an average of 16.2 percentage points more than placebo. All children received lifestyle modifications including reduced-calorie diets and increased physical activity.
More than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks, assuming patients stayed on treatment. In the trial, 85% of children started with moderate to severe obesity, and nearly half had at least one obesity-related complication such as high blood pressure, high cholesterol, or sleep apnea.
Wegovy is already approved to treat obesity in children ages 12 and older. No approved medications currently exist for children under 12. Novo said Wegovy's safety and tolerability in children matched results from adult trials, with no safety concerns related to growth or pubertal development observed.
The World Obesity Federation estimated roughly 177 million children and teens ages 5 to 19 had obesity in 2025, with projections rising to 228 million by 2040.
Dr. Andrea Traina, Novo's medical director lead of obesity, noted the two-year study does not establish whether treating obesity earlier changes its long-term trajectory or what maintenance looks like as children grow into adulthood, calling this an "evidence gap" for future research.